<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621005</url>
  </required_header>
  <id_info>
    <org_study_id>SBP prophylaxis</org_study_id>
    <nct_id>NCT05621005</nct_id>
  </id_info>
  <brief_title>Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients</brief_title>
  <official_title>Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samar Atef Sebaweh Mohammed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial&#xD;
      peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad spectrum&#xD;
      antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's&#xD;
      diarrhea and prevention of hepatic encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prophylaxis against spontaneous bacterial peritonitis (SBP) in cirrhotic patients recovered&#xD;
      from an episode of SBP using Norfloxacin 400 mg/day is currently established standard of&#xD;
      care. Recently we are facing the growing challenge of standard SBP prophylaxis lacking&#xD;
      efficacy as extended spectrum beta-lactamases and fluoro-quinolone resistant bacteria in&#xD;
      isolates of patients on Norfloxacin.&#xD;
&#xD;
      Prophylaxis against Hepatorenal Syndrome in decompensated liver cirrhosis is limited to IV&#xD;
      administration of Albumin in patients who develop SBP and the prevention of SBP using&#xD;
      Norfloxacin.&#xD;
&#xD;
      this study aims to investigate the effectiveness of Rifaximin in decompensated cirrhotic&#xD;
      patients against SBP as a secondary prophylaxis measure and Hepatorenal Syndrome.&#xD;
&#xD;
      our study was non inferiority prospective non randomized controlled trial The study enrolled&#xD;
      patients with chronic liver disease and ascites who were monitored at outpatient clinics or&#xD;
      who were admitted to Ain Shams University hospitals.104 patients with decompensated liver&#xD;
      cirrhosis were enrolled in the study, The Control Group (n=52), to receive standard of care&#xD;
      treatment &amp; Norfloxacin prophylaxis for the decompensated liver disease and a second&#xD;
      Treatment Group (n=52) who will receive Rifaximin prophylaxis in addition to the original&#xD;
      management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2022</completion_date>
  <primary_completion_date type="Actual">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study design: non inferiority prospective non randomized controlled trial&#xD;
Study population and setting:&#xD;
The study enrolled patients with chronic liver disease and ascites who were monitored at outpatient clinics or who were admitted to Ain Shams University hospitals.&#xD;
Sample size: 104 patients with decompensated liver cirrhosis were enrolled in the study. The Control Group (n=52), to receive standard of care treatment &amp; Norfloxacin prophylaxis for the decompensated liver disease and a second Treatment Group (n=52) who will receive Rifaximin prophylaxis in addition to the original management.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>secondary prophylaxis of SBP and primary prophylaxis for hepatorenal syndrome</measure>
    <time_frame>3 months</time_frame>
    <description>our study was conducted to test the efficacy of Rifaximin in prevention of recurrence of SBP and occurrence of hepatorenal syndrome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Ascites Infection</condition>
  <arm_group>
    <arm_group_label>treatment group or Rifaximin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>they received Rifaximin 550 milligram every 12 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group or Norfloxacin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>they received Norfloxacin 400 milligram per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin 550 milligram Oral Tablet [XIFAXAN]</intervention_name>
    <description>Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months</description>
    <arm_group_label>control group or Norfloxacin group</arm_group_label>
    <arm_group_label>treatment group or Rifaximin group</arm_group_label>
    <other_name>xifaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Decompensated cirrhotic patients (Child B or C, ascetic patients).&#xD;
&#xD;
          2. Adult male/female aged &gt;18 years old.&#xD;
&#xD;
          3. History or evidence of previous attack of SBP and currently clinically free from SBP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent abdominal surgery.&#xD;
&#xD;
          2. Patients with renal impairment (serum creatinine &gt;1.5mg/dl) at baseline.&#xD;
&#xD;
          3. Patients on renal replacement therapy (RRT) at baseline.&#xD;
&#xD;
          4. Sonographic evidence of Nephropathy other than grade I nephropathy in ascetic patients&#xD;
&#xD;
          5. intraabdominal source of infection (e.g. intra-abdominal abscesses, cholecystitis or&#xD;
             acute pancreatitis).&#xD;
&#xD;
          6. Patients with current evidence of upper Urinary tract infection.&#xD;
&#xD;
          7. Other comorbidities affecting the patient survival e.g. significant cardiac disease,&#xD;
             pulmonary disease, portal vein thrombosis, hepatocellular carcinoma or other&#xD;
             malignancies, etc.&#xD;
&#xD;
          8. Sepsis.&#xD;
&#xD;
          9. Current or recent treatment with nephrotoxic drugs or contrast material injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samar A Sebaweh, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>assistant lecturer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine Ain Shams university</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017 Feb 28;9(6):293-299. doi: 10.4254/wjh.v9.i6.293.</citation>
    <PMID>28293378</PMID>
  </reference>
  <reference>
    <citation>Dong T, Aronsohn A, Gautham Reddy K, Te HS. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. Dig Dis Sci. 2016 Dec;61(12):3621-3626. doi: 10.1007/s10620-016-4313-0. Epub 2016 Sep 21.</citation>
    <PMID>27655104</PMID>
  </reference>
  <reference>
    <citation>Fernandez J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology. 2016 Jun;63(6):2019-31. doi: 10.1002/hep.28330. Epub 2016 Jan 11.</citation>
    <PMID>26528864</PMID>
  </reference>
  <reference>
    <citation>Moreau R, Elkrief L, Bureau C, Perarnau JM, Thevenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grange JD, Carbonell N, Bronowicki JP, Payance A, Rautou PE, Valla D, Gault N, Lebrec D; NORFLOCIR Trial Investigators. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology. 2018 Dec;155(6):1816-1827.e9. doi: 10.1053/j.gastro.2018.08.026. Epub 2018 Aug 23.</citation>
    <PMID>30144431</PMID>
  </reference>
  <reference>
    <citation>Soriano G, Guarner C, Teixido M, Such J, Barrios J, Enriquez J, Vilardell F. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology. 1991 Feb;100(2):477-81. doi: 10.1016/0016-5085(91)90219-b.</citation>
    <PMID>1985045</PMID>
  </reference>
  <reference>
    <citation>Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013 Mar;28(3):450-5. doi: 10.1111/jgh.12070.</citation>
    <PMID>23216382</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 12, 2022</study_first_submitted>
  <study_first_submitted_qc>November 12, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Samar Atef Sebaweh Mohammed</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>Rifaximin</keyword>
  <keyword>Norflixacin</keyword>
  <keyword>Spontaneous bacterial peritonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>individual participant data will be shared including inclusion criteria and the final statical results</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>3 to 5 months</ipd_time_frame>
    <ipd_access_criteria>through the official e mail and the publishing journal</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

